Cancer to bone: a fatal attraction.

Tumor metastasis: molecular insights and evolving paradigms. Cell (2011) 10.34

Tumour exosome integrins determine organotropic metastasis. Nature (2015) 4.09

VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell (2011) 3.23

Unravelling the complexity of metastasis - molecular understanding and targeted therapies. Nat Rev Cancer (2011) 2.64

The osteogenic niche promotes early-stage bone colonization of disseminated breast cancer cells. Cancer Cell (2015) 1.91

Metastatic stem cells: sources, niches, and vital pathways. Cell Stem Cell (2014) 1.88

In vivo molecular imaging of chemokine receptor CXCR4 expression in patients with advanced multiple myeloma. EMBO Mol Med (2015) 1.83

The cancer stem cell niche: how essential is the niche in regulating stemness of tumor cells? Cell Stem Cell (2015) 1.66

Bone-derived IGF mediates crosstalk between bone and breast cancer cells in bony metastases. Cancer Res (2012) 1.65

Tumor-induced osteoclast miRNA changes as regulators and biomarkers of osteolytic bone metastasis. Cancer Cell (2013) 1.62

Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res (2012) 1.58

The TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to Bone. Cancer Cell (2015) 1.55

The ADP receptor P2RY12 regulates osteoclast function and pathologic bone remodeling. J Clin Invest (2012) 1.45

Comparative effectiveness on survival of zoledronic acid versus pamidronate in multiple myeloma. Leuk Lymphoma (2014) 1.41

miR-218 directs a Wnt signaling circuit to promote differentiation of osteoblasts and osteomimicry of metastatic cancer cells. J Biol Chem (2012) 1.39

Hypoxia-driven pathways in bone development, regeneration and disease. Nat Rev Rheumatol (2012) 1.36

Metastatic colonization by circulating tumour cells. Nature (2016) 1.31

Excess TGF-β mediates muscle weakness associated with bone metastases in mice. Nat Med (2015) 1.27

Global secretome analysis identifies novel mediators of bone metastasis. Cell Res (2012) 1.22

Zoledronic acid has differential antitumor activity in the pre- and postmenopausal bone microenvironment in vivo. Clin Cancer Res (2014) 1.16

Hedgehog signaling inhibition blocks growth of resistant tumors through effects on tumor microenvironment. Cancer Res (2011) 1.15

Molecular pathways: VCAM-1 as a potential therapeutic target in metastasis. Clin Cancer Res (2012) 1.14

Twenty-five years of PTHrP progress: from cancer hormone to multifunctional cytokine. J Bone Miner Res (2012) 1.14

Targeting tumor-stromal interactions in bone metastasis. Pharmacol Ther (2013) 1.12

Disclosing the CXCR4 expression in lymphoproliferative diseases by targeted molecular imaging. Theranostics (2015) 1.11

Targeting of Runx2 by miR-135 and miR-203 Impairs Progression of Breast Cancer and Metastatic Bone Disease. Cancer Res (2015) 1.09

Polarization of prostate cancer-associated macrophages is induced by milk fat globule-EGF factor 8 (MFG-E8)-mediated efferocytosis. J Biol Chem (2014) 1.08

Bone marrow mesenchymal stem cells and TGF-β signaling in bone remodeling. J Clin Invest (2014) 1.08

RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08

The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-myeloma effects. Leukemia (2012) 1.07

Bioengineered human tumor within a bone niche. Biomaterials (2014) 1.05

Antagonism of inhibitor of apoptosis proteins increases bone metastasis via unexpected osteoclast activation. Cancer Discov (2012) 1.04

Regulation of cancer metastasis by cell-free miRNAs. Biochim Biophys Acta (2014) 1.02

Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron (2011) 1.01

Metastatic tumors to the jaws and mouth. Head Neck Pathol (2014) 1.00

Small-molecule SMAC mimetics as new cancer therapeutics. Pharmacol Ther (2014) 0.99

Multiorgan metastasis of human HER-2+ breast cancer in Rag2-/-;Il2rg-/- mice and treatment with PI3K inhibitor. PLoS One (2012) 0.99

miR-429 inhibits migration and invasion of breast cancer cells in vitro. Int J Oncol (2014) 0.98

Integrin αvβ6 promotes an osteolytic program in cancer cells by upregulating MMP2. Cancer Res (2014) 0.97

Molecular mechanisms of bone metastasis and associated muscle weakness. Clin Cancer Res (2014) 0.97

Osteoclasts: New Insights. Bone Res (2013) 0.97

Maspin reprograms the gene expression profile of prostate carcinoma cells for differentiation. Genes Cancer (2011) 0.97

Inhibition of osteoclastogenesis and inflammatory bone resorption by targeting BET proteins and epigenetic regulation. Nat Commun (2014) 0.96

WISP1/CCN4: a potential target for inhibiting prostate cancer growth and spread to bone. PLoS One (2013) 0.95

Targeting RANKL in metastasis. Bonekey Rep (2014) 0.95

Skeletal metastasis: treatments, mouse models, and the Wnt signaling. Chin J Cancer (2013) 0.95

Tissue-engineered models of human tumors for cancer research. Expert Opin Drug Discov (2015) 0.95

Emerging Biological Principles of Metastasis. Cell (2017) 0.94

Skeletal metastases from breast cancer: pathogenesis of bone tropism and treatment strategy. Clin Exp Metastasis (2015) 0.94

Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia (2012) 0.94

In vivo tibial compression decreases osteolysis and tumor formation in a human metastatic breast cancer model. J Bone Miner Res (2013) 0.93

Bone marrow fat: linking adipocyte-induced inflammation with skeletal metastases. Cancer Metastasis Rev (2014) 0.92

The role of vascular endothelial growth factor in metastatic prostate cancer to the skeleton. Prostate Cancer (2013) 0.92

Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res (2012) 0.91

Thrombospondin-1 regulates bone homeostasis through effects on bone matrix integrity and nitric oxide signaling in osteoclasts. J Bone Miner Res (2015) 0.91

Distinctive properties of metastasis-initiating cells. Genes Dev (2016) 0.91

Surviving at a distance: organ specific metastasis. Trends Cancer (2015) 0.90

Navigating the bone marrow niche: translational insights and cancer-driven dysfunction. Nat Rev Rheumatol (2015) 0.90

Bone metastasis and the metastatic niche. J Mol Med (Berl) (2015) 0.90

The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol (2012) 0.89

DLC1-dependent parathyroid hormone-like hormone inhibition suppresses breast cancer bone metastasis. J Clin Invest (2014) 0.89

A microRNA code for prostate cancer metastasis. Oncogene (2015) 0.89

Tissue engineering a surrogate niche for metastatic cancer cells. Biomaterials (2015) 0.88

Osteoclasts-Key Players in Skeletal Health and Disease. Microbiol Spectr (2016) 0.88

Marrow adipocyte-derived CXCL1 and CXCL2 contribute to osteolysis in metastatic prostate cancer. Clin Exp Metastasis (2015) 0.88

Macrophages: Their Emerging Roles in Bone. J Bone Miner Res (2015) 0.88

Features and prognostic impact of distant metastasis in patients with stage IV lung adenocarcinoma harboring EGFR mutations: importance of bone metastasis. Clin Exp Metastasis (2014) 0.87

Understanding and targeting osteoclastic activity in prostate cancer bone metastases. Curr Mol Med (2013) 0.87

Targeting IL-6 and RANKL signaling inhibits prostate cancer growth in bone. Clin Exp Metastasis (2014) 0.87

Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res (2013) 0.87

Ecology meets cancer biology: the cancer swamp promotes the lethal cancer phenotype. Oncotarget (2015) 0.86

Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. Breast Cancer Res (2014) 0.86

Bone metastasis: the importance of the neighbourhood. Nat Rev Cancer (2016) 0.86

Cancer-associated muscle weakness: What's bone got to do with it? Bonekey Rep (2015) 0.86

MicroRNAs and Osteolytic Bone Metastasis: The Roles of MicroRNAs in Tumor-Induced Osteoclast Differentiation. J Clin Med (2015) 0.86

ABCC5 supports osteoclast formation and promotes breast cancer metastasis to bone. Breast Cancer Res (2012) 0.86

Protein expression changes during human triple negative breast cancer cell line progression to lymph node metastasis in a xenografted model in nude mice. Cancer Biol Ther (2012) 0.86

Parathyroid hormone-related protein inhibits DKK1 expression through c-Jun-mediated inhibition of β-catenin activation of the DKK1 promoter in prostate cancer. Oncogene (2013) 0.86

Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells. Endocr Relat Cancer (2012) 0.86

Curcuminoids block TGF-β signaling in human breast cancer cells and limit osteolysis in a murine model of breast cancer bone metastasis. J Nat Prod (2012) 0.85

Effect of (Neo)adjuvant zoledronic acid on disease-free and overall survival in clinical stage II/III breast cancer. Br J Cancer (2012) 0.85

AR-regulated TWEAK-FN14 pathway promotes prostate cancer bone metastasis. Cancer Res (2014) 0.85

Electrochemotherapy is effective in the treatment of rat bone metastases. Clin Exp Metastasis (2013) 0.85

Targeting Breast Cancer Metastasis. Breast Cancer (Auckl) (2015) 0.85

Dasatinib as a bone-modifying agent: anabolic and anti-resorptive effects. PLoS One (2012) 0.85

Osteoblast-derived WNT-induced secreted protein 1 increases VCAM-1 expression and enhances prostate cancer metastasis by down-regulating miR-126. Oncotarget (2014) 0.84

Prostate cancer and parasitism of the bone hematopoietic stem cell niche. Crit Rev Eukaryot Gene Expr (2012) 0.84

microRNA regulation of Wnt signaling pathways in development and disease. Cell Signal (2015) 0.84

Phospholipases of mineralization competent cells and matrix vesicles: roles in physiological and pathological mineralizations. Int J Mol Sci (2013) 0.84

Development of a preclinical orthotopic xenograft model of ewing sarcoma and other human malignant bone disease using advanced in vivo imaging. PLoS One (2014) 0.84

Animal Models of Bone Metastasis. Vet Pathol (2015) 0.84

Tumour-derived miRNAs and bone metastasis. Bonekey Rep (2015) 0.83

Mechanisms of action of bisphosphonates in oncology: a scientific concept evolving from antiresorptive to anticancer activities. Bonekey Rep (2013) 0.83

Molecular alterations that drive breast cancer metastasis to bone. Bonekey Rep (2015) 0.83

A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer. PLoS One (2013) 0.83

IL-11 produced by breast cancer cells augments osteoclastogenesis by sustaining the pool of osteoclast progenitor cells. BMC Cancer (2013) 0.82

Stromal-Initiated Changes in the Bone Promote Metastatic Niche Development. Cell Rep (2015) 0.82

Cancer-associated osteoclast differentiation takes a good look in the miR(NA)ror. Cancer Cell (2013) 0.82

Runx2-Smad signaling impacts the progression of tumor-induced bone disease. Int J Cancer (2014) 0.82

Cancer-associated mesenchymal stem cells aggravate tumor progression. Front Cell Dev Biol (2015) 0.82

Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

Osteoblastic cells regulate the haematopoietic stem cell niche. Nature (2003) 19.60

Targeted disruption of Cbfa1 results in a complete lack of bone formation owing to maturational arrest of osteoblasts. Cell (1997) 18.91

Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell (2005) 18.20

Identification of the haematopoietic stem cell niche and control of the niche size. Nature (2003) 18.17

A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86

VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature (2005) 15.57

Mesenchymal and haematopoietic stem cells form a unique bone marrow niche. Nature (2010) 15.28

The novel zinc finger-containing transcription factor osterix is required for osteoblast differentiation and bone formation. Cell (2002) 15.20

Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med (2009) 13.74

Metastasis to bone: causes, consequences and therapeutic opportunities. Nat Rev Cancer (2002) 12.45

Integrins in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer (2010) 11.16

The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med (2003) 10.67

Mechanisms of bone metastasis. N Engl J Med (2004) 10.40

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study. J Clin Oncol (2010) 9.29

The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol (2002) 8.27

Interferons, immunity and cancer immunoediting. Nat Rev Immunol (2006) 8.23

Genetic regulation of osteoclast development and function. Nat Rev Genet (2003) 7.94

Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev (1999) 7.69

Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med (2000) 6.98

Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treat Rev (2001) 6.57

RANK is essential for osteoclast and lymph node development. Genes Dev (1999) 5.85

Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction. J Exp Med (2006) 5.63

Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst (2004) 5.39

Osteoclasts degrade endosteal components and promote mobilization of hematopoietic progenitor cells. Nat Med (2006) 5.33

The amazing osteocyte. J Bone Miner Res (2011) 5.32

TGF-beta signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest (1999) 5.30

ATF4 is a substrate of RSK2 and an essential regulator of osteoblast biology; implication for Coffin-Lowry Syndrome. Cell (2004) 5.27

TGFbeta signalling: a complex web in cancer progression. Nat Rev Cancer (2010) 5.27

Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24

Metastasis: quantitative analysis of distribution and fate of tumor emboli labeled with 125 I-5-iodo-2'-deoxyuridine. J Natl Cancer Inst (1970) 4.88

Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science (2008) 4.71

TGF-beta1-induced migration of bone mesenchymal stem cells couples bone resorption with formation. Nat Med (2009) 4.58

CXCR4 regulates growth of both primary and metastatic breast cancer. Cancer Res (2004) 4.53

Human prostate cancer metastases target the hematopoietic stem cell niche to establish footholds in mouse bone marrow. J Clin Invest (2011) 4.43

Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol (1998) 4.41

The terminology issue for myeloid-derived suppressor cells. Cancer Res (2007) 4.37

Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A (2005) 4.20

Osteopontin is a hematopoietic stem cell niche component that negatively regulates stem cell pool size. J Exp Med (2005) 4.17

Contribution of platelets to tumour metastasis. Nat Rev Cancer (2011) 4.16

Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood (1999) 4.13

Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95

Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis. Nature (2008) 3.82

Chemosensitization of acute myeloid leukemia (AML) following mobilization by the CXCR4 antagonist AMD3100. Blood (2008) 3.77

RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature (2010) 3.66

Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest (1996) 3.44

NF-kappaB in breast cancer cells promotes osteolytic bone metastasis by inducing osteoclastogenesis via GM-CSF. Nat Med (2006) 3.40

Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol (2009) 3.37

CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood (2009) 3.37

Tumor-derived JAGGED1 promotes osteolytic bone metastasis of breast cancer by engaging notch signaling in bone cells. Cancer Cell (2011) 3.32

Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol (2005) 3.31

The S100A8-serum amyloid A3-TLR4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol (2008) 3.30

Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A (2008) 3.27

Small integrin-binding ligand N-linked glycoproteins (SIBLINGs): multifunctional proteins in cancer. Nat Rev Cancer (2008) 3.04

Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res (2001) 2.89

Preferential adhesion of prostate cancer cells to a human bone marrow endothelial cell line. J Natl Cancer Inst (1998) 2.83

Increased incidence of bone metastases in hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2001) 2.75

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial. Lancet Oncol (2010) 2.74

Molecular biology of bone metastasis. Mol Cancer Ther (2007) 2.71

Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res (2006) 2.69

MMP-7 promotes prostate cancer-induced osteolysis via the solubilization of RANKL. Cancer Cell (2005) 2.65

Expression of CXCR4 and CXCL12 (SDF-1) in human prostate cancers (PCa) in vivo. J Cell Biochem (2003) 2.62

Symptoms during cancer pain treatment following WHO-guidelines: a longitudinal follow-up study of symptom prevalence, severity and etiology. Pain (2001) 2.59

ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes Dev (2009) 2.59

Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. Nat Med (2000) 2.54

Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status. J Natl Cancer Inst (1996) 2.51

Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med (1995) 2.50

Calcification of multipotent prostate tumor endothelium. Cancer Cell (2008) 2.49

New insights into the molecular mechanisms of action of bisphosphonates. Curr Pharm Des (2003) 2.44

Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res (2007) 2.41

Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36

Monocyte/macrophage infiltration in tumors: modulators of angiogenesis. J Leukoc Biol (2006) 2.33

Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases. Cancer Res (2000) 2.32

Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest (2004) 2.30

Suppression of CXCL12 production by bone marrow osteoblasts is a common and critical pathway for cytokine-induced mobilization. Blood (2009) 2.25

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23

Platelet and osteoclast beta3 integrins are critical for bone metastasis. Proc Natl Acad Sci U S A (2003) 2.21

Fusion of tumour cells with bone marrow-derived cells: a unifying explanation for metastasis. Nat Rev Cancer (2008) 2.17

Effects of denosumab in patients with bone metastases with and without previous bisphosphonate exposure. J Bone Miner Res (2010) 2.15

Imaging transforming growth factor-beta signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat Med (2009) 2.10

Pathobiology of transforming growth factor beta in cancer, fibrosis and immunologic disease, and therapeutic considerations. Lab Invest (2007) 2.08

Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol (2009) 2.01

Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol (2000) 1.99

Osteomimetic properties of prostate cancer cells: a hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment. Prostate (1999) 1.92

Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91

Cooperative interactions between activating transcription factor 4 and Runx2/Cbfa1 stimulate osteoblast-specific osteocalcin gene expression. J Biol Chem (2005) 1.91

Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res (2007) 1.89

Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res (1991) 1.87

Runx2 association with progression of prostate cancer in patients: mechanisms mediating bone osteolysis and osteoblastic metastatic lesions. Oncogene (2009) 1.87

CXCL12/CXCR4 signaling activates Akt-1 and MMP-9 expression in prostate cancer cells: the role of bone microenvironment-associated CXCL12. Prostate (2006) 1.86

Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85

Myeloma cells suppress bone formation by secreting a soluble Wnt inhibitor, sFRP-2. Blood (2005) 1.85

TGF-beta regulates the mechanical properties and composition of bone matrix. Proc Natl Acad Sci U S A (2005) 1.83

Impaired intranuclear trafficking of Runx2 (AML3/CBFA1) transcription factors in breast cancer cells inhibits osteolysis in vivo. Proc Natl Acad Sci U S A (2005) 1.83

Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma. Blood (2001) 1.83

Platelet-derived thrombospondin-1 is a critical negative regulator and potential biomarker of angiogenesis. Blood (2010) 1.81

Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood (2004) 1.78

Overexpression of CXCR4 on human CD34+ progenitors increases their proliferation, migration, and NOD/SCID repopulation. Blood (2003) 1.78

Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer. Cancer Res (2007) 1.77

A multigenic program mediating breast cancer metastasis to bone. Cancer Cell (2003) 16.86

Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res (2007) 6.76

Use of the stromal cell-derived factor-1/CXCR4 pathway in prostate cancer metastasis to bone. Cancer Res (2002) 5.00

Teriparatide and osseous regeneration in the oral cavity. N Engl J Med (2010) 3.08

Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res (2015) 2.74

Molecular biology of bone metastasis. Mol Cancer Ther (2007) 2.71

Skeletal localization and neutralization of the SDF-1(CXCL12)/CXCR4 axis blocks prostate cancer metastasis and growth in osseous sites in vivo. J Bone Miner Res (2004) 2.36

A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A (2003) 2.23

Differential stem- and progenitor-cell trafficking by prostaglandin E2. Nature (2013) 1.99

Transforming growth factor-beta stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem (2002) 1.95

Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res (2007) 1.89

Bone turnover mediates preferential localization of prostate cancer in the skeleton. Endocrinology (2005) 1.85

In vivo visualization of metastatic prostate cancer and quantitation of disease progression in immunocompromised mice. Cancer Biol Ther (2003) 1.77

Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy. J Mammary Gland Biol Neoplasia (2005) 1.75

Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment. PLoS One (2009) 1.72

Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69

Effect of long-term oral bisphosphonates on implant wound healing: literature review and a case report. J Periodontol (2007) 1.69

GLI2-mediated melanoma invasion and metastasis. J Natl Cancer Inst (2010) 1.68

TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastases. Cancer Res (2010) 1.68

Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab (2004) 1.67

Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-kappaB ligand pathway. Cancer Res (2005) 1.65

Stromal factors involved in prostate carcinoma metastasis to bone. Cancer (2003) 1.63

A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone. Cancer Res (2009) 1.61

Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone. PLoS One (2008) 1.60

Hematopoietic stem cells regulate mesenchymal stromal cell induction into osteoblasts thereby participating in the formation of the stem cell niche. Stem Cells (2008) 1.58

Cyclophosphamide creates a receptive microenvironment for prostate cancer skeletal metastasis. Cancer Res (2012) 1.58

An in vivo mouse model for human prostate cancer metastasis. Neoplasia (2008) 1.54

The calcium-sensing receptor is required for normal calcium homeostasis independent of parathyroid hormone. J Clin Invest (2003) 1.53

TGF-β/SMAD/GLI2 signaling axis in cancer progression and metastasis. Cancer Res (2011) 1.49

JunB as a downstream mediator of PTHrP actions in cementoblasts. J Bone Miner Res (2005) 1.47

Extracellular calcium as a candidate mediator of prostate cancer skeletal metastasis. Cancer Res (2006) 1.45

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation. Mol Endocrinol (2006) 1.44

Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology (2005) 1.44

Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone (2007) 1.40

Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest (2015) 1.38

Cyclin D1 as a target for the proliferative effects of PTH and PTHrP in early osteoblastic cells. J Bone Miner Res (2007) 1.35

Metastasis and bone loss: advancing treatment and prevention. Cancer Treat Rev (2010) 1.32

The critical role of the bone microenvironment in cancer metastases. Mol Cell Endocrinol (2009) 1.31

Parathyroid hormone and parathyroid hormone-related protein exert both pro- and anti-apoptotic effects in mesenchymal cells. J Biol Chem (2002) 1.28

Anabolic actions of PTH (1-34): use of a novel tissue engineering model to investigate temporal effects on bone. Bone (2005) 1.28

Rap1GAP inhibits tumor growth in oropharyngeal squamous cell carcinoma. Am J Pathol (2006) 1.26

Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem (2013) 1.25

Skeletal metastasis: Established and emerging roles of parathyroid hormone related protein (PTHrP). Cancer Metastasis Rev (2006) 1.25

TGF-β in cancer and bone: implications for treatment of bone metastases. Bone (2010) 1.20

Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology (2002) 1.19

Vascular endothelial growth factor contributes to the prostate cancer-induced osteoblast differentiation mediated by bone morphogenetic protein. Cancer Res (2004) 1.19

PTHrP signaling targets cyclin D1 and induces osteoblastic cell growth arrest. J Bone Miner Res (2005) 1.18

Osteal macrophages support physiologic skeletal remodeling and anabolic actions of parathyroid hormone in bone. Proc Natl Acad Sci U S A (2014) 1.18

Impact of the mitogen-activated protein kinase pathway on parathyroid hormone-related protein actions in osteoblasts. J Biol Chem (2004) 1.16

Tumor expressed PTHrP facilitates prostate cancer-induced osteoblastic lesions. Int J Cancer (2008) 1.15

Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases. Prostate (2010) 1.15

The release profiles and bioactivity of parathyroid hormone from poly(lactic-co-glycolic acid) microspheres. Biomaterials (2004) 1.14

Molecular mechanisms and treatment of bone metastasis. Expert Rev Mol Med (2008) 1.12

Pre-clinical mouse models of human prostate cancer and their utility in drug discovery. Curr Protoc Pharmacol (2010) 1.12

Guanosine nucleotides inhibit different syndromes of PTHrP excess caused by human cancers in vivo. J Clin Invest (2002) 1.12

RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitro. PLoS One (2013) 1.08

Detection and isolation of circulating tumor cells in urologic cancers: a review. Neoplasia (2004) 1.07

Parathyroid hormone mediates hematopoietic cell expansion through interleukin-6. PLoS One (2010) 1.06

The role of TGF-β in bone metastasis: novel therapeutic perspectives. Bonekey Rep (2012) 1.06

Role of Bcl2 in osteoclastogenesis and PTH anabolic actions in bone. J Bone Miner Res (2008) 1.05

TGF-β in the Bone Microenvironment: Role in Breast Cancer Metastases. Cancer Microenviron (2011) 1.05

Assessing new bone formation in neonatal calvarial organ cultures. Methods Mol Biol (2008) 1.03

Antiresorptives and osteonecrosis of the jaw. J Evid Based Dent Pract (2012) 1.02

The impact of primary hyperparathyroidism on the oral cavity. J Clin Endocrinol Metab (2006) 1.01

An irradiation-altered bone marrow microenvironment impacts anabolic actions of PTH. Endocrinology (2011) 1.01

Roles of bone marrow cells in skeletal metastases: no longer bystanders. Cancer Microenviron (2011) 1.01

The soluble interleukin-6 receptor is a mediator of hematopoietic and skeletal actions of parathyroid hormone. J Biol Chem (2013) 1.00

Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference. Clin Cancer Res (2008) 1.00

The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells. Cancer Lett (2006) 0.98

Effect of zoledronate on oral wound healing in rats. Clin Cancer Res (2010) 0.98

Anti-placental growth factor reduces bone metastasis by blocking tumor cell engraftment and osteoclast differentiation. Cancer Res (2010) 0.97

Ossicle and vossicle implant model systems. Methods Mol Biol (2008) 0.96

Mechanisms of osteoblastic metastases: role of endothelin-1. Clin Orthop Relat Res (2003) 0.95

Hepatocyte growth factor inhibits anoikis by induction of activator protein 1-dependent cyclooxygenase-2. Implication in head and neck squamous cell carcinoma progression. J Biol Chem (2002) 0.94

Actions of bisphosphonates in animal models of breast cancer. Breast Cancer Res (2001) 0.94

Protein kinase Calpha regulates Ets1 transcriptional activity in invasive breast cancer cells. Int J Oncol (2003) 0.94

Updates on osteonecrosis of the jaw. Curr Opin Support Palliat Care (2010) 0.94

Prevalence of prostate cancer metastases after intravenous inoculation provides clues into the molecular basis of dormancy in the bone marrow microenvironment. Neoplasia (2012) 0.94

Endothelial interleukin-6 defines the tumorigenic potential of primary human cancer stem cells. Stem Cells (2014) 0.93

The midregion, nuclear localization sequence, and C terminus of PTHrP regulate skeletal development, hematopoiesis, and survival in mice. FASEB J (2010) 0.93

Molecular mechanisms of bone metastasis and therapeutic implications. Clin Orthop Relat Res (2003) 0.92

Inhibitory effects of megakaryocytic cells in prostate cancer skeletal metastasis. J Bone Miner Res (2011) 0.91

Proteoglycan 4, a novel immunomodulatory factor, regulates parathyroid hormone actions on hematopoietic cells. Am J Pathol (2011) 0.91

Amelioration of type I diabetes-induced osteoporosis by parathyroid hormone is associated with improved osteoblast survival. J Cell Physiol (2012) 0.91

Halofuginone inhibits the establishment and progression of melanoma bone metastases. Cancer Res (2012) 0.91

Skeletal metastases: decreasing tumor burden by targeting the bone microenvironment. J Cell Biochem (2007) 0.90

Adrenomedullin is a cross-talk molecule that regulates tumor and mast cell function during human carcinogenesis. Am J Pathol (2006) 0.90

c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions. PLoS One (2012) 0.90

Proteoglycan 4: a dynamic regulator of skeletogenesis and parathyroid hormone skeletal anabolism. J Bone Miner Res (2012) 0.89

The multifaceted actions of PTHrP in skeletal metastasis. Future Oncol (2012) 0.89

Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer. Clin Cancer Res (2011) 0.88

Decreased autocrine EGFR signaling in metastatic breast cancer cells inhibits tumor growth in bone and mammary fat pad. PLoS One (2012) 0.87

Skeletal homeostasis in tissue-engineered bone. J Orthop Res (2003) 0.87

Calcium release channel RyR2 regulates insulin release and glucose homeostasis. J Clin Invest (2015) 0.87

Activation of the Wnt pathway through AR79, a GSK3β inhibitor, promotes prostate cancer growth in soft tissue and bone. Mol Cancer Res (2013) 0.87

Parathyroid hormone-related protein drives a CD11b+Gr1+ cell-mediated positive feedback loop to support prostate cancer growth. Cancer Res (2013) 0.87

Estrogenic side effects of androgen deprivation therapy. Rev Urol (2007) 0.87

Animal models of bone metastasis. Cancer Treat Res (2004) 0.86

Synthesis and erosion properties of PEG-containing polyanhydrides. Macromol Biosci (2007) 0.86

Nuclear localization of parathyroid hormone-related peptide confers resistance to anoikis in prostate cancer cells. Endocr Relat Cancer (2012) 0.86